CO2017010292A2 - Composiciones farmacéuticas para terapias combinadas - Google Patents
Composiciones farmacéuticas para terapias combinadasInfo
- Publication number
- CO2017010292A2 CO2017010292A2 CONC2017/0010292A CO2017010292A CO2017010292A2 CO 2017010292 A2 CO2017010292 A2 CO 2017010292A2 CO 2017010292 A CO2017010292 A CO 2017010292A CO 2017010292 A2 CO2017010292 A2 CO 2017010292A2
- Authority
- CO
- Colombia
- Prior art keywords
- insulin
- blood glucose
- glucose level
- sensitivity
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 abstract 3
- 239000008103 glucose Substances 0.000 abstract 3
- 230000003914 insulin secretion Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144040P | 2015-04-07 | 2015-04-07 | |
| PCT/US2016/026146 WO2016164413A1 (en) | 2015-04-07 | 2016-04-06 | Pharmaceutical compositions for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017010292A2 true CO2017010292A2 (es) | 2018-01-05 |
Family
ID=57072872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0010292A CO2017010292A2 (es) | 2015-04-07 | 2017-10-10 | Composiciones farmacéuticas para terapias combinadas |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10894054B2 (enExample) |
| EP (1) | EP3280421B1 (enExample) |
| JP (1) | JP6879931B2 (enExample) |
| KR (1) | KR20170132879A (enExample) |
| CN (1) | CN107613986A (enExample) |
| AR (1) | AR104195A1 (enExample) |
| AU (1) | AU2016246524B2 (enExample) |
| BR (1) | BR112017021311A2 (enExample) |
| CA (1) | CA2981507A1 (enExample) |
| CL (2) | CL2017002538A1 (enExample) |
| CO (1) | CO2017010292A2 (enExample) |
| CR (1) | CR20170456A (enExample) |
| EA (1) | EA036757B1 (enExample) |
| EC (1) | ECSP17073004A (enExample) |
| ES (1) | ES2974281T3 (enExample) |
| IL (2) | IL254772A0 (enExample) |
| MA (1) | MA41083A1 (enExample) |
| MX (1) | MX2017012893A (enExample) |
| NI (1) | NI201700121A (enExample) |
| PE (1) | PE20180034A1 (enExample) |
| SM (1) | SMT202400104T1 (enExample) |
| SV (1) | SV2017005539A (enExample) |
| TN (1) | TN2017000426A1 (enExample) |
| TW (1) | TW201642869A (enExample) |
| WO (1) | WO2016164413A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| ES2860423T3 (es) | 2014-05-28 | 2021-10-05 | Childrens Hospital Med Ct | Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida |
| WO2016061464A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intetine using pluripotent stem cells and methods of making and using same |
| HK1249847A1 (zh) | 2015-03-09 | 2018-11-16 | Intekrin Therapeutics, Inc. | 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| JP2019519478A (ja) | 2016-04-19 | 2019-07-11 | ユレカ・ソシエテ・ア・レスポンサビリテ・リミテＵｒｅｋａ Ｓａｒｌ | ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法 |
| JP6963882B2 (ja) | 2016-05-05 | 2021-11-10 | チルドレンズ ホスピタル メディカル センター | 胃底部組織のインビトロでの製造のための方法及び当該方法と関連した組成物 |
| EP3534907A4 (en) | 2016-11-04 | 2020-06-24 | Children's Hospital Medical Center | COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASE |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| CA3077442A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| WO2019126626A1 (en) | 2017-12-21 | 2019-06-27 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| US10806735B2 (en) * | 2018-04-24 | 2020-10-20 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
| SG11202100533VA (en) | 2018-07-26 | 2021-02-25 | Childrens Hospital Med Ct | Hepato-biliary-pancreatic tissues and methods of making same |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CA3112026A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| WO2020081766A1 (en) * | 2018-10-18 | 2020-04-23 | Avolynt | Use of sglt2 inhibitors to treat primary sclerosing cholangitis |
| EP3883578A4 (en) | 2018-11-20 | 2022-07-27 | Sparrow Pharmaceuticals, Inc. | METHODS OF CORTICOSTEROID ADMINISTRATION |
| WO2020108830A1 (en) * | 2018-11-30 | 2020-06-04 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| AU2020247991A1 (en) * | 2019-03-26 | 2021-10-21 | Intercept Pharmaceuticals, Inc. | Methods of diagnosis and treatment of liver diseases using obeticholic acid |
| EP3946333A1 (en) * | 2019-04-04 | 2022-02-09 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| US12497597B2 (en) | 2019-05-31 | 2025-12-16 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| WO2021029656A1 (ko) * | 2019-08-14 | 2021-02-18 | 주식회사 바이오톡스텍 | 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물 |
| CA3201686A1 (en) * | 2021-01-14 | 2022-07-21 | Fabiola Terzi | Method for treating chronic kidney diseases |
| IL316907A (en) | 2022-05-16 | 2025-01-01 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS |
| WO2023225507A1 (en) * | 2022-05-16 | 2023-11-23 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
| CN119894533A (zh) * | 2022-06-08 | 2025-04-25 | 科吉恩治疗股份有限公司 | 用于启动、调节和调整重量减轻的方法和组合物及其治疗应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747445A (en) * | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
| US20030109467A1 (en) | 2001-11-15 | 2003-06-12 | Isis Pharmaceuticals Inc. | Antisense modulation of human FXR expression |
| WO2000037077A1 (en) | 1998-12-23 | 2000-06-29 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| AU2409600A (en) | 1999-01-07 | 2000-07-24 | Tularik Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| TR200102805T2 (tr) * | 1999-03-29 | 2002-04-22 | F.Hoffmann-La Roche Ag | Glikokinaz aktivatörleri |
| US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
| ATE303399T1 (de) | 2001-03-12 | 2005-09-15 | Intercept Pharmaceuticals Inc | Steroide als agonisten für fxr |
| EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| WO2003086303A2 (en) * | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| EP1680414A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED INDAZOLE-O-GLUCOSIDE |
| AR048376A1 (es) * | 2003-08-01 | 2006-04-26 | Janssen Pharmaceutica Nv | C- glicosidos heterociclos fusionados sustituidos |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| DK2712617T3 (en) | 2004-03-12 | 2017-02-13 | Intercept Pharmaceuticals Inc | Treatment of fibrosis with Fxr ligands. |
| US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| WO2007022518A2 (en) * | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
| PT3524261T (pt) * | 2005-08-19 | 2024-01-12 | Amylin Pharmaceuticals Llc | Exendina para o tratamento da diabetes e redução do peso corporal |
| EP1962838B1 (en) | 2005-12-19 | 2011-09-28 | GlaxoSmithKline LLC | Farnesoid x receptor agonists |
| BRPI0707794A2 (pt) | 2006-02-14 | 2011-05-10 | Intercept Pharmaceuticals Inc | compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos |
| JP5225984B2 (ja) | 2006-05-24 | 2013-07-03 | イーライ リリー アンド カンパニー | Ｆｘｒを調節する化合物及び方法 |
| AU2007267606A1 (en) | 2006-05-24 | 2007-12-06 | Eli Lilly And Company | FXR agonists |
| ES2523591T3 (es) | 2006-06-27 | 2014-11-27 | Intercept Pharmaceuticals Inc. | Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR |
| EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| US20080300235A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
| US20080299118A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for the Treatment of Malignancies |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
| US20090163474A1 (en) | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| US20090215748A1 (en) | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| US20100056546A1 (en) * | 2008-09-04 | 2010-03-04 | Auspex Pharmaceuticals, Inc. | Sulfonylurea inhibitors of atp-sensitive potassium channels |
| US8685934B2 (en) | 2009-05-27 | 2014-04-01 | Bristol-Myers Squibb Company | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| DE112011100657T5 (de) * | 2010-02-24 | 2013-02-28 | Relypsa, Inc. | Amin-polymere zur verwendung als gallensäuresequestriermittel |
| ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| US9775556B2 (en) | 2010-05-26 | 2017-10-03 | Andre′ A. DiMino | Apparatus and method for uroflowmetry |
| CN103108722B (zh) | 2010-09-15 | 2015-12-02 | 住友电气工业株式会社 | 激光加工方法 |
| WO2012106581A1 (en) * | 2011-02-03 | 2012-08-09 | The University Of Chicago | Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction |
| EA201990211A1 (ru) | 2012-06-19 | 2019-06-28 | Интерсепт Фармасьютикалз, Инк. | Получение, применение и твердые формы обетихолевой кислоты |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| ES2847002T3 (es) | 2013-05-14 | 2021-07-30 | Intercept Pharmaceuticals Inc | Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide |
| EA036404B1 (ru) | 2015-02-06 | 2020-11-06 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
-
2016
- 2016-04-06 PE PE2017001987A patent/PE20180034A1/es unknown
- 2016-04-06 BR BR112017021311A patent/BR112017021311A2/pt not_active IP Right Cessation
- 2016-04-06 EP EP16777168.2A patent/EP3280421B1/en active Active
- 2016-04-06 MX MX2017012893A patent/MX2017012893A/es unknown
- 2016-04-06 TN TNP/2017/000426A patent/TN2017000426A1/en unknown
- 2016-04-06 CR CR20170456A patent/CR20170456A/es unknown
- 2016-04-06 WO PCT/US2016/026146 patent/WO2016164413A1/en not_active Ceased
- 2016-04-06 CN CN201680029144.7A patent/CN107613986A/zh active Pending
- 2016-04-06 CA CA2981507A patent/CA2981507A1/en not_active Abandoned
- 2016-04-06 JP JP2017553131A patent/JP6879931B2/ja active Active
- 2016-04-06 US US15/564,799 patent/US10894054B2/en active Active
- 2016-04-06 SM SM20240104T patent/SMT202400104T1/it unknown
- 2016-04-06 MA MA41083A patent/MA41083A1/fr unknown
- 2016-04-06 KR KR1020177031857A patent/KR20170132879A/ko not_active Ceased
- 2016-04-06 EA EA201792203A patent/EA036757B1/ru unknown
- 2016-04-06 AU AU2016246524A patent/AU2016246524B2/en not_active Ceased
- 2016-04-06 ES ES16777168T patent/ES2974281T3/es active Active
- 2016-04-07 TW TW105110879A patent/TW201642869A/zh unknown
- 2016-04-07 AR ARP160100929A patent/AR104195A1/es unknown
-
2017
- 2017-09-28 IL IL254772A patent/IL254772A0/en unknown
- 2017-10-05 SV SV2017005539A patent/SV2017005539A/es unknown
- 2017-10-05 NI NI201700121A patent/NI201700121A/es unknown
- 2017-10-06 CL CL2017002538A patent/CL2017002538A1/es unknown
- 2017-10-10 CO CONC2017/0010292A patent/CO2017010292A2/es unknown
- 2017-11-01 EC ECIEPI201773004A patent/ECSP17073004A/es unknown
-
2018
- 2018-04-19 CL CL2018001007A patent/CL2018001007A1/es unknown
-
2019
- 2019-07-29 IL IL268316A patent/IL268316B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017021311A2 (pt) | 2018-06-26 |
| EA036757B1 (ru) | 2020-12-17 |
| PE20180034A1 (es) | 2018-01-09 |
| MX2017012893A (es) | 2018-01-15 |
| EP3280421A1 (en) | 2018-02-14 |
| CR20170456A (es) | 2018-06-13 |
| CN107613986A (zh) | 2018-01-19 |
| JP6879931B2 (ja) | 2021-06-02 |
| ES2974281T3 (es) | 2024-06-26 |
| SMT202400104T1 (it) | 2024-05-14 |
| CL2017002538A1 (es) | 2018-04-20 |
| WO2016164413A1 (en) | 2016-10-13 |
| CA2981507A1 (en) | 2016-10-13 |
| AU2016246524B2 (en) | 2021-04-01 |
| IL268316A (en) | 2019-09-26 |
| NI201700121A (es) | 2018-01-10 |
| US20180117065A1 (en) | 2018-05-03 |
| EP3280421B1 (en) | 2023-12-27 |
| ECSP17073004A (es) | 2018-02-28 |
| KR20170132879A (ko) | 2017-12-04 |
| US10894054B2 (en) | 2021-01-19 |
| AR104195A1 (es) | 2017-07-05 |
| EA201792203A1 (ru) | 2018-02-28 |
| EP3280421A4 (en) | 2019-08-28 |
| TW201642869A (zh) | 2016-12-16 |
| CL2018001007A1 (es) | 2018-06-15 |
| AU2016246524A1 (en) | 2017-10-26 |
| SV2017005539A (es) | 2019-01-18 |
| IL254772A0 (en) | 2017-12-31 |
| IL268316B (en) | 2022-02-01 |
| MA41083A1 (fr) | 2018-05-31 |
| TN2017000426A1 (en) | 2019-04-12 |
| JP2018510900A (ja) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017010292A2 (es) | Composiciones farmacéuticas para terapias combinadas | |
| EA201790568A1 (ru) | Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени | |
| AR092925A1 (es) | Derivados de exendina-4 como agonistas duales de glp1 / glucagon | |
| EA201590759A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
| CL2016003069A1 (es) | Composición para tratar la diabetes mellitus, que comprende conjugados de variantes de insulina humana y una región fc, y además comprende un conjugado compuesto por un agonista doble de glp-/glucagón y una región fc | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| CO6361944A2 (es) | Combinacion de una insulina y un agonista de glp-1 | |
| EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
| PH12019502655A1 (en) | Acylated insulin compound | |
| BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
| MX2020007462A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| BR112018002520A2 (pt) | Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer | |
| MX2015008555A (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
| CL2015001574A1 (es) | Terapia combinada para el cancer | |
| MX391734B (es) | COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE IgG PARA EL TRATAMIENTO DE UNA INMUNODEFICIENCIA. | |
| MX2016006375A (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
| PH12019550216A1 (en) | Compositions for treatment of hyperglycemia in diabetes mellitus patients | |
| Klossowski | Maculopapular rash: case report | |
| Upasi | Homoeopathic remedies: the physics of healing with microdoses | |
| Toussaint | Placebo-Controlled Trials | |
| TH172399A (th) | การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน | |
| CL2009000621A1 (es) | Uso de un agonista selectivo del receptor s1p1 para preparar un medicamento util en el tratamiento de enfermedades o trastornos asociados con un sistema inmune activado. | |
| EA201991119A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną |